Pliant Therapeutics (PLRX) Research & Development (2019 - 2026)
Pliant Therapeutics (PLRX) reported Research & Development of $13.6 million for Q1 2026, down 68.73% year-over-year from $43.4 million in Q1 2025, and down 12.84% quarter-over-quarter from $15.6 million in Q4 2025.
Pliant Therapeutics (PLRX) Research & Development (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of Research & Development data on file, last reported at $13.6 million in Q1 2026.
- Research & Development for Q1 2026 came in at $13.6 million, down 68.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $79.3 million (down 54.84% YoY), and the FY2025 annual result was $109.2 million, down 35.53% from the prior year.
- Research & Development slipped to $13.6 million in Q1 2026 per PLRX's latest filing, from $15.6 million in the prior quarter.
- Over five years, Research & Development peaked at $47.8 million in Q3 2024 and troughed at $13.6 million in Q1 2026.
- A 5-year average of $30.4 million and a median of $32.2 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2026: Research & Development surged 47.67% in 2024, then slumped 68.73% in 2026.
- A 5-year view of Research & Development shows it stood at $25.1 million in 2022, then surged by 32.13% to $33.2 million in 2023, then grew by 16.91% to $38.8 million in 2024, then tumbled by 59.83% to $15.6 million in 2025, then dropped by 12.84% to $13.6 million in 2026.
- Business Quant data shows PLRX's Research & Development at $13.6 million in Q1 2026, $15.6 million in Q4 2025, and $17.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -58.00 Mn |
| 10 | Pliant Therapeutics | 71.07 Mn | 71.07 Mn | - | 13.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.58 Mn |
| Dec 31, 2025 | 15.59 Mn |
| Sep 30, 2025 | 17.94 Mn |
| Jun 30, 2025 | 32.20 Mn |
| Mar 31, 2025 | 43.44 Mn |
| Dec 31, 2024 | 38.79 Mn |
| Sep 30, 2024 | 47.75 Mn |
| Jun 30, 2024 | 45.62 Mn |
| Mar 31, 2024 | 37.15 Mn |
| Dec 31, 2023 | 33.18 Mn |
| Sep 30, 2023 | 32.34 Mn |
| Jun 30, 2023 | 33.00 Mn |
| Mar 31, 2023 | 29.27 Mn |
| Dec 31, 2022 | 25.11 Mn |
| Sep 30, 2022 | 24.61 Mn |
| Jun 30, 2022 | 26.34 Mn |
| Mar 31, 2022 | 20.88 Mn |
| Dec 31, 2021 | 18.75 Mn |
| Sep 30, 2021 | 21.05 Mn |
| Jun 30, 2021 | 19.22 Mn |